Ibio, Inc. key statistics and ratios

In fiscal 2026, Ibio, Inc. had return on equity of -65.7%, an operating margin of -35141.0%, debt equal to 0.0% of equity and a current ratio of 7.85. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ibio, Inc.: financial ratios, annual
Fiscal year	2011Jun 2011	2012Jun 2012	2013Jun 2013	2014Jun 2014	2015Jun 2015	2016Jun 2016	2017Jun 2017	2018Jun 2018	2019Jun 2019	2020Jun 2020	2021Jun 2021	2022Jun 2022	2023Jun 2023	2024Jun 2024	2025Jun 2025	2026Jun 2026
Gross margin	—	—	—	—	—	—	—	—	—	57.1%	38.3%	—	—	—	—	—
Operating margin	<−999%	−730.4%	−662.1%	<−999%	−360.1%	<−999%	<−999%	<−999%	−782.4%	−854.9%	<−999%	<−999%	—	<−999%	<−999%	<−999%
Net margin	<−999%	−444.5%	−615.5%	<−999%	−357.9%	<−999%	<−999%	<−999%	−871.8%	<−999%	−978.8%	<−999%	—	<−999%	<−999%	<−999%
Free-cash-flow margin	<−999%	−470.7%	−482.2%	<−999%	−256.0%	−858.6%	<−999%	<−999%	−738.1%	−880.5%	<−999%	<−999%	—	<−999%	<−999%	<−999%
Return on equity	—	−178.4%	−110.3%	−65.7%	−76.5%	−92.3%	−154.2%	−128.4%	−188.9%	−55.6%	−28.1%	−58.5%	−164.9%	−135.7%	−101.5%	−65.7%
Return on assets	−165.5%	−66.4%	−64.8%	−46.3%	−69.8%	−30.5%	−33.2%	−40.7%	−47.8%	−26.3%	−19.2%	−40.8%	−92.5%	−71.2%	−70.8%	−54.0%
Asset turnover	0.07	0.15	0.11	0.03	0.20	0.03	0.01	0.01	0.05	0.03	0.02	0.02	—	0.01	0.02	0.00
Current ratio	0.60	1.92	1.55	9.91	8.01	10.43	4.26	8.00	1.39	11.79	15.74	1.48	1.19	4.08	1.59	7.85
Debt to equity	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.1%	0.6%	—	85.7%	4.6%	9.5%	0.0%
Interest cover (operating income ÷ interest)	n/m	n/m	n/m	—	—	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m	n/m
R&D as % of revenue	592.9%	390.1%	340.7%	925.9%	188.8%	332.9%	>999%	897.7%	271.3%	218.1%	421.3%	521.6%	—	>999%	>999%	>999%
Capital spending as % of revenue	0.2%	0.1%	0.7%	2.0%	0.7%	7.2%	335.8%	210.4%	45.6%	65.8%	207.5%	389.1%	—	93.3%	4.0%	578.0%

US$ thousands unless shown otherwise. Fiscal quarters.

Ibio, Inc.: financial ratios, quarterly
Quarter	2025 Q1Sept 2024	2025 Q2Dec 2024	2025 Q3Mar 2025	2025 Q4Jun 2025	2026 Q1Sept 2025	2026 Q2Dec 2025	2026 Q3Mar 2026	2026 Q4Jun 2026
Operating margin	—	<−999%	—	<−999%	<−999%	—	—	—
Net margin	—	<−999%	—	<−999%	<−999%	—	—	—
Free-cash-flow margin	—	<−999%	—	<−999%	<−999%	—	—	—
Current ratio	3.37	1.76	1.12	1.59	8.39	9.04	11.88	7.85
Debt to equity	4.0%	4.6%	—	—	—	—	—	—
R&D as % of revenue	—	938.5%	—	>999%	>999%	—	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · June 30, 2026

What it owns · $99m

Short-term assets $92mLonger-term assets $7m

What it owes, and who funded it · $99m

Short-term liabilities $12mLonger-term liabilities $2mShareholders' equity $86m

Short-term assets cover short-term liabilities $92m of assets due within a year against $12m of liabilities due within a year.
Short-term assets cover long-term liabilities $92m short-term assets against $2m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$35m against $53,000 of interest.

From Ibio, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

8 /100

Weak moat

How hard Ibio's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Net income has been a median -45.5% of total assets over 10 years.
Durability 10 / 20

Operating margin has been a median -1865.3%; its worst year was -35141.0%.
Cash conversion 0 / 20

Free cash flow was positive in 0 of 10 years, at a median -2338.7% of revenue.
Discipline 0 / 20

The diluted share count rose 4047.4% over five years; stock-based pay has been a median 163.0% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: IBIO vs LSTA AIM vs IBIO CLDX vs IBIO CLNN vs IBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ibio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ibio, Inc.